Women whose breast cancers need estrogen to grow are often treated for five or more years with medications to lower estrogen ...

No improvement in overall survival (OS) was observed with palbociclib (Verzenio) plus endocrine therapy versus capecitabine ...

Paolo Tarantino, MD, PhD, discusses elacestrant as a treatment option for patients with ESR1-mutated metastatic breast cancer in the second line.

Nanoparticles (NPs) and nanosized objects are being incorporated rapidly into clinical medicine and particularly into the field of medical oncology, including breast cancer. A number of novel ...

Selection of breast cancer displaying HER2 amplification and hormonal receptor expression is a mandatory requirement to administer anti-HER2-directed drugs and endocrine therapy. Thus ...

A new study led by a George Washington University Cancer Center researcher found that cold therapy protects breast cancer ...

A new breast health center operated by RWJBarnabas Health and Rutgers Cancer Institute is now open on Route 18.

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Aditya Bardia, MD, MPH, FASCO, medical oncologist, UCLA Health, provides new insights on the role of TROP2-directed antibody drug conjugates (ADCs) for patients with breast cancer.

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...